

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

DRAGON PHARMACEUTICALS INC

Form 10-Q

May 15, 2002

1

U.S. Securities and Exchange Commission
Washington, D.C. 20549

Form 10-Q

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended March 31, 2002

Commission file number 0-27937

DRAGON PHARMACEUTICAL INC.
(Exact name of small business issuer as specified in its charter)

Florida 65-0142474
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)

1055 West Hastings Street, Suite 1900
Vancouver, British Columbia
Canada V6E 2E9
(Address of principal executive offices)

(604) 669-8817
(Issuer's telephone number)

(Former address if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No

Number of shares of common stock outstanding as of March 31, 2002: 20,331,000

2

Part 1. Financial Information

Item 1. Financial Statements

3

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Consolidated Balance Sheets
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

	March 31, 2002	D
ASSETS		
Current		
Cash and short term securities	\$ 5,791,160	\$
Accounts receivable	1,813,412	
Inventories	1,110,936	
Prepaid and deposits	270,431	
Total current assets	8,985,939	
Fixed assets	2,534,096	
Investment in Hepatitis B vaccine project - related party	3,790,000	
Refundable investment deposits - related party	-	
Patent rights - related party	500,000	
Licence and permit	3,889,721	
Total assets	\$ 19,699,756	\$
=====		
LIABILITIES AND STOCKHOLDERS' EQUITY		
Liabilities		
Current		
Bank loans	\$ 2,609,168	\$
Accounts payable and accrued liabilities	1,130,522	
Management fees payable - related parties	25,833	
Total current liabilities	3,765,523	
Minority interests	-	
Commitments (Note 13)		
Stockholders' Equity		
Share capital		
Authorized: 50,000,000 common shares at par value of \$0.001 each		
Issued and outstanding: 20,331,000 common shares (December 31, 2000 - 16,700,000)	20,331	
Additional paid in capital	26,624,741	
Accumulated other comprehensive (loss)	(29,112)	
Accumulated deficit	(10,681,727)	
Total stockholders' equity	15,934,233	
Total liabilities and stockholders' equity	\$ 19,699,756	\$

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

The accompanying notes are an integral part of these financial statements.

4

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES

Consolidated Statements of Stockholders' Equity
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

	Common stock		Additional	Compre-	
	Shares	Amount	paid-in	Hensive	Def
			capital	Income	accumul
				(loss)	
Balance, December 31, 2000	16,700,000	\$ 16,700	\$20,000,897	-	\$ (6,008,
Exercise of stock options for cash	131,000	131	65,369	-	
Issuance of common stock pursuant to a private placement at \$2.00 per share, net of share issuance costs of \$490,000 in September	3,500,000	3,500	6,506,500	-	
Other comprehensive income - foreign currency translation	-	-	-	580	
Comprehensive (loss) - net (loss) for the year	-	-	-	(3,735,305)	(3,735,
Stock option compensation	-	-	51,975	-	
Comprehensive (loss)			\$ (3,734,725)		
			=====		
Balance, December 31, 2001	20,331,000	\$20,331	\$26,624,741		\$ (9,743,

The accompanying notes are an integral part of these financial statements.

5

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES

Consolidated Statements of Stockholders' Equity
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

	Common stock		Additional	Compre-	
	Shares	Amount	paid-in	hensive	De
			capital	income	accu
				(loss)	
Balance, December 31, 2001	20,331,000	\$ 20,331	\$ 26,624,741	-	\$ (9,
Other comprehensive income					
- foreign currency translation	-	-	-	(4,104)	
Comprehensive (loss)					
- net (loss) for the year	-	-	-	(937,878)	(
Comprehensive (loss)				\$ (941,982)	
				=====	
Balance, March 31, 2002	20,331,000	\$ 20,331	\$ 26,624,741		\$ (10,
					=====

The accompanying notes are an integral part of these financial statements.

6

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Consolidated Statements of Operations
Three Months Ended March 31, 2002 and 2001
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

	2002	2001
Sales	\$ 1,372,808	\$ 664,414
Cost of sales	190,524	146,920
Gross profit	1,182,284	517,494
Selling, general and administrative expenses	(1,096,460)	(1,125,808)
Depreciation of fixed assets and amortization of licence and permit	(181,658)	(153,814)
Net write off of land-use right and fixed assets	(1,225)	-
Research and development expenses	(755,572)	(40,200)
New market development	(52,588)	(99,880)
Provision for doubtful debts	(25,856)	(36,826)
Loan interest expense	(40,410)	(33,993)
Stock-based compensation	-	(51,975)

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

Operating loss	(971,485)	(1,025,002)
Interest income	33,607	65,259

Loss before minority interest	(937,878)	(959,743)
Minority interest	-	103,560

Net (loss) for the period	\$ (937,878)	\$ (856,183)
=====		
(Loss) per share		
Basic and diluted	\$ (0.05)	\$ (0.05)
=====		
Weighted average number of common shares outstanding		
Basic and diluted	20,331,000	16,701,233
=====		

The accompanying notes are an integral part of these financial statements.

7

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Consolidated Statements of Cash Flows
Three Months Ended March 31, 2002 and 2001
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

	2002	2001

Cash flows from (used in) operating activities		
Net (loss) for the year	\$ (937,878)	\$ (856,183)
Adjustments to reconcile net loss to net cash used in operating activities:		
- stock-based compensation expense	-	51,975
- depreciation of fixed assets and amortization of licence and permit	181,658	197,323
- minority interests	-	(103,560)
- net write off of land-use right and fixed assets	1,225	-
- provision for doubtful debts	25,856	36,826
Changes in non-cash working capital items:		
- accounts receivable	(557,582)	101,974
- inventories	(15,076)	(148,974)
- prepaid expenses and deposits	(130,091)	(19,465)
- accounts payable and accrued liabilities	(188,416)	(76,005)
- management fees payable - related parties	(208,167)	-

	(1,828,471)	(816,089)

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

Cash flows used in investing activities		
Purchase of fixed assets	(44,392)	(327,932)
(Increase) decrease in restricted funds	299,985	(192,357)
Acquisition of Patent rights	(500,000)	-
Acquisition of balance of Huaxin	(1,400,000)	-
Refundable investment deposits	400,000	-

	(1,244,407)	(520,289)

Cash flows from financing activities		
Loan proceeds	(278,177)	277,842
Proceeds from issuance of shares, net of issuance costs	-	3,000

	(278,177)	280,842

Foreign exchange (gain) loss on cash held in foreign currency	(3,884)	506

Increase (decrease) in cash and cash equivalents	(3,354,939)	(1,055,030)
Cash and cash equivalents, beginning of period	6,306,129	4,092,702

Cash and cash equivalents, end of period	\$ 2,951,190	\$ 3,037,672
=====		

The accompanying notes are an integral part of these financial statements.

8

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES Notes to Consolidated Financial Statements March 31, 2002

(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

1. Nature of Business

The Company was formed on August 22, 1989 as First Geneva Investments Inc. under the laws of the State of Florida. The Company changed its name to Dragon Pharmaceuticals Inc. on August 31, 1998. Pursuant to a share exchange agreement, dated July 29, 1998, the Company acquired 100% of the issued and outstanding shares of Allwin Newtech Ltd. ("Allwin") by issuing 7,000,000 common shares of the Company. This transaction is accounted for as a reverse acquisition.

Allwin was incorporated under the laws of British Virgin Islands on February 10, 1998. Pursuant to a Sino-Foreign Co-operative Company Contract, dated April 18, 1998, Allwin and a Chinese corporation formed a limited liability company under the Chinese law, named as Sanhe Kailong Bio-pharmaceutical Co., Ltd. ("Kailong"), located in Hebei Province, China. Allwin has a 95% interest in Kailong. Pursuant to another Sino-foreign Co-operative Company Contract, dated July 27, 1999, Allwin completed the

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

acquisition of a 75% interest in Nanjing Huaxin Bio-pharmaceutical Co. Ltd. ("Huaxin"). In January 2002, the Company acquired the balance of Huaxin for \$1,400,000. Kailong is inactive and Huaxin is in the business of research and development, production and sales of pharmaceutical products in China. Allwin Biotrade Inc. ("Biotrade") was incorporated under the laws of British Virgin Islands on June 6, 2000 for the purpose of marketing and distributing biopharmaceutical products outside China. Dragon Pharmaceuticals (Canada) Inc. ("Dragon Canada") was incorporated in British Columbia, Canada on September 15, 2000 for the purpose of researching and developing new biopharmaceutical products.

2. Significant Accounting Policies

(a) Basis of Consolidation

(i) These consolidated financial statements include the accounts of the Company and its subsidiaries, Allwin, Kailong, Huaxin, Biotrade and Dragon Canada. All inter-company transactions and balances have been eliminated.

(ii) Under the terms of Sino-Foreign Joint Venture Contract, Huaxin's board of directors consists of five directors of which the Company has the right to select three directors including the chairman. Except for (1) amending Huaxin's articles of association; (2) liquidating Huaxin; (3) increasing or decreasing Huaxin's registered capital; (4) mortgaging Huaxin's assets; and (5) merging Huaxin, which transactions require unanimous approval by Huaxin's board, the Company controls Huaxin in the ordinary course of business. Because the Company has a controlling financial interest in Huaxin, and controls Huaxin's operations in the ordinary course of business, the Company has accounted for Huaxin using the consolidated method of accounting as opposed to using the equity method.

9

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES

Notes to Consolidated Financial Statements

March 31, 2002

(Expressed in U.S. Dollars)

(Unaudited - Prepared by Management)

2. Significant Accounting Policies (continued)

(b) Principles of Accounting

These financial statements are stated in US Dollars and have been prepared in accordance with accounting principles generally accepted in the United States.

(c) Fixed Assets

Depreciation is based on the estimated useful lives of the assets and is computed using the straight-line method. Fixed assets are recorded at cost. Depreciation is provided over the following useful lives:

Motor vehicle	10 years
Lab equipment	8 years
Office equipment and furniture	5 years
Leasehold improvements	Term of lease (10 years)
Production equipment	10 years

(d) Foreign Currency Transactions

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

The parent company, Allwin, Kailong, Huaxin, Biotrade and Dragon Canada maintain their accounting records in their functional currencies (i.e., U.S. dollars, U.S. dollars, Renminbi Yuan, Renminbi Yuan, U.S. dollars and Canadian dollars respectively). They translate foreign currency transactions into their functional currency in the following manner.

At the transaction date, each asset, liability, revenue and expense is translated into the functional currency by the use of the exchange rate in effect at that date. At the period end, monetary assets and liabilities are translated into the functional currency by using the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in operations.

(e) Foreign Currency Translations

Assets and liabilities of the foreign subsidiaries (whose functional currency is Renminbi Yuan or Canadian dollars) are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Revenue and expenses are translated at average exchange rate. Gain and losses from such translations are included in stockholders' equity, as a component of other comprehensive income.

10

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

2. Significant Accounting Policies (continued)

(f) Accounting Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(g) Advertising Expenses

The Company expenses advertising costs as incurred. There were no advertising expenses incurred by the Company during the period ended March 31, 2002 and 2001.

(h) Income Taxes

The Company has adopted Statement of Financial Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes", which requires the Company to recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns using the liability method. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse.

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

(i) Comprehensive Income

The Company has adopted SFAS No. 130, "Reporting Comprehensive Income", which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. SFAS No. 130 did not change the current accounting treatments for components of comprehensive income.

11

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

2. Significant Accounting Policies (continued)

(j) Financial Instruments and Concentration of Risks

Fair value of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.

The carrying value of cash and cash equivalents, term deposits, accounts receivable, bank loans, accounts payable and accrued liabilities approximate their fair value because of the short-term nature of these instruments. The Company places its cash and cash equivalents with high credit quality financial institutions. The Company routinely maintains balances in a financial institution beyond the insured amount. As of March 31, 2002, the Company had deposits of \$45,000 above insured limits.

The Company is operating in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between U.S. dollars and the Chinese currency RMB. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and trade receivables, the balances of which are stated on the balance sheet. The Company places its cash in high credit quality financial institutions. Concentration of credit risk with respect to trade receivables are limited due to the Company's' large number of diverse customers in different locations in China. The Company does not require collateral or other security to support financial instruments subject to credit risk.

(k) Licence and Permit

Licence and permit, in relation to the production and sales of pharmaceutical products in China, is amortized on a straight-line basis over ten years.

The carrying value of licence and permit is reviewed by management at least annually and impairment losses, if any, are recognized when the

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

expected non-discounted future operating cash flows derived from the related product licence acquired are less than the carrying value of such licence and permit. In the event of an impairment in the value of the licence and permit, the discounted cash flows method is used to arrive at the estimated fair value of such licence and permit.

12

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

2. Significant Accounting Policies (continued)

(l) Cash and Cash Equivalents

Cash equivalents usually consist of highly liquid investments which are readily convertible into cash with maturities of three months or less. As at March 31, 2002, cash equivalents consist of commercial papers and redeemable term deposits.

(m) Inventories

Inventories are stated at the lower of cost and replacement cost with respect to raw materials and the lower of cost and net realizable value with respect to finished goods. Cost includes direct material, direct labour and overheads. Cost is calculated using the first-in, first-out method. Net realizable value represents the anticipated selling price less further costs for completion and distribution.

(n) Revenue Recognition

Sales revenue is recognized upon the delivery of goods to customers.

(o) Stock-based Compensation

The Company adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123 (SFAS 123), "Accounting for Stock-based Compensation". SFAS 123 encourages, but does not require, companies to adopt a fair value based method for determining expense related to stock-based compensation. The Company continues to account for stock-based compensation issued to employees and directors using the intrinsic value method as prescribed under Accounting Principles Board Opinion (APB) No. 25, "Accounting for Stock Issued to Employees" and related Interpretations.

(p) Loss Per Share

Loss per share is computed using the weighted average number of shares outstanding during the period. The Company adopted SFAS No. 128, "Earnings per share". Diluted loss per share is equal to the basic loss per share because common stock equivalents consisting of options to acquire 2,969,500 common shares and warrants to acquire 3,200,000 common shares that are outstanding at March 31, 2002 are anti-dilutive, however, they may be dilutive in future.

13

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

Notes to Consolidated Financial Statements

March 31, 2002

(Expressed in U.S. Dollars)

(Unaudited - Prepared by Management)

2. Significant Accounting Policies (continued)

(q) New Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 141 (SFAS 141), Business Combinations. SFAS 141 applies to all business combinations initiated after June 30, 2001. The SFAS 141 applies to all business combinations accounted for using the purchase method for which the date of acquisition is July 1, 2001, or later. The adoption of SFAS 141 will not have an impact on the Company's financial statements.

In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 142 (SFAS 142), Goodwill and Other Intangible Assets. The provisions of SFAS 142 are required to be applied starting with fiscal years beginning after December 15, 2001 with earlier application permitted for entities with fiscal years beginning after March 15, 2001 provided that the first interim financial statements have not been previously issued. The Statement is required to be applied at the beginning of the entity's fiscal year and to be applied to all goodwill and other intangible assets recognized in its financial statements to that date. The adoption of SFAS 142 will not have an impact on the Company's financial statements.

In August 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 143 (SFAS 143), Asset Retirement Obligations. SFAS 143 establishes accounting standards for recognition and measurement of a liability for the costs of assets retirement obligations. Under SFAS 143, the costs of retiring an asset will be recorded as a liability when the retirement obligation arises and will be amortized to expense over the life of the asset. The adoption of SFAS 143 will not have an impact on the Company's financial statements.

In October, 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 144 (SFAS 144), Accounting for the Impairment or Disposal of Long-lived Assets. SFAS 144 supersedes SFAS 121, Accounting for the Impairment of Long-lived Assets and Long-lived Assets to be Disposed Of, and APB Opinion 30, Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions, for segments of a business to be disposed of. SFAS 144 is effective for fiscal years beginning after December 15, 2001. The adoption of SFAS 144 will not have an impact on the Company's financial statements.

14

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES

Notes to Consolidated Financial Statements

March 31, 2002

(Expressed in U.S. Dollars)

(Unaudited - Prepared by Management)

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

3. Restricted Funds

	March 31, 2002
Term deposits held as collateral against bank loans	\$2,839,970
Cash and cash equivalents	2,951,190
Cash and short term securities	\$5,791,160

4. Accounts Receivable

	March 31, 2002
Trade receivable	\$1,776,194
Allowance for doubtful accounts	(151,823)
	1,624,371
Other receivable	189,041
	\$1,813,412

5. Inventories

	March 31, 2002
Raw materials	\$146,105
Finished goods	173,271
Work in progress	791,560
	\$1,110,936

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

6. Fixed Assets

	March 31, 2002	
	Cost	Accumulated depreciation
Motor vehicles	\$100,317	\$35,674
Office equipment and furniture	335,348	101,616
Leasehold improvements	998,404	248,691
Production and lab equipment	2,039,274	553,266
	\$3,473,343	\$939,247
	December 31, 2001	
	Cost	Accumulated depreciation
Motor vehicles	\$100,329	\$31,657
Office equipment and furniture	267,104	85,935
Leasehold improvements	990,940	221,652
Production and lab equipment	2,020,137	504,657
	\$3,378,510	\$843,901

For the three months ended March 31, 2002, depreciation expenses totalled \$95,675 (2001 - \$84,755). The majority of fixed assets are located in China.

7. Investment in Hepatitis B Vaccine Project - Related Party

	March 31, 2002
Hepatitis B Vaccine Project	\$4,000,000
Less: Valuation allowance	(210,000)
	\$3,790,000

- (a) Pursuant to an agreement dated October 6, 2000, the Company paid \$4,000,000 for the acquisition of certain assets and technology relating to the production of Hepatitis B vaccine. The vendor of the transaction is a

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

company named Alphatech Bioengineering Limited, incorporated in Hong Kong, and one of the two shareholders of which is a director and senior officer of the Company.

16

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

7. Investment in Hepatitis B Vaccine Project - Related Party (continued)

(b) Pursuant to an amended agreement dated June 5, 2001, in the event that the Company failed to find a joint venture partner, establish a production facility for the vaccine project or sell the project to a third party within nine months from the date of this amended agreement, Dr. Longbin Liu, a senior officer and director of the Company and one of the shareholders of Alphatech, demands to repurchase the project from the Company. The repurchase price will be \$4.0 million payable as follows:

- (i) \$500,000 at the date of repurchase; and
- (ii) the balance to be paid within eighteen (18) months of the date of repurchase with interest at 6% per annum. The interest will be accrued from six months after the date of repurchase.

Subsequent to March 31, 2002, the Company decided not to pursue the Project and Dr. Liu demanded to repurchase the Project on the agreed terms.

8. Refundable Investment deposits - Related Party

	March 31, 2002
-----	-----
Guangzhou Recomgen Biotech Co. Ltd.	
- Tissue Plasminogen Activator ("TPA") Project	-
Less: Valuation allowance	-
-----	-----
	-
=====	=====

During the year 2000, the Company paid \$400,000 to Guangzhou Recomgen Biotech Co. Ltd. ("Guangzhou Recomgen"), a company incorporated in China, for the funding of its TPA research and development programs with the intention of acquiring the technology. Guangzhou Recomgen is controlled by a senior officer and a director of the Company. The Company decided not to proceed with the funding and the acquisition due to financial market and economic conditions and the \$400,000 was repaid in January 2002.

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

9. Patent Rights - Related Party

Pursuant to an agreement dated January 14, 2002, the Company entered into a Patent Development Agreement with the President and a company controlled by the President entitling the Company to acquire one patent filed in the United States related to the discovery of a new gene or protein. Consideration for the right to acquire the patent was payment of US\$500,000 and the issuance of warrants to acquire 1,000,000 common shares of the Company at a price of \$2.50 per share for a period of five years. The patent may be acquired prior to January 14, 2005 at no additional cost other than the reasonable legal costs of obtaining the patent.

17

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

10. Bank Loans

	March 31, 2002
RMB 7,800,000, bearing interest at 5.265% per annum and due on January 31, 2003. The loan is secured by the term deposit.	\$942,200
RMB 4,000,000, bearing interest at 5.265% per annum and due on August 20, 2002. The loan is secured by the term deposit.	483,178
RMB 1,400,000 bearing interest at 5.265% per annum and due on July 26, 2002. The loan is secured by the term deposit.	169,113
RMB 2,300,000 bearing interest at 5.265% per annum and due on January 18, 2002. The loan is secured by the term deposit.	-
RMB 3,150,000 bearing interest at 5.265% per annum and due on April 4, 2002. The loan is secured by the term deposit.	380,504
RMB 3,700,000 bearing interest at 5.265% per annum and due on June 19, 2002. The loan is secured by the term deposit.	446,941
RMB 1,555,000 bearing interest at 5.265% per annum and due on January 31, 2003. The loan is secured by the term deposit.	187,232
Total	\$2,609,168

The weighted average interest rate was 5.265% and 5.48% for the three months ended March 31, 2002 and 2001.

18

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

11. Income Taxes

- (a) Kailong and Huaxin are subject to income taxes in China on its taxable income as reported in its statutory accounts at a tax rate in accordance with the relevant income tax laws applicable to Sino-foreign equity joint venture enterprises. However, pursuant to the same income tax laws, Kailong and Huaxin are fully exempt from income tax for five years starting from their first profit-making year followed by a 15% corporation tax rate for the next three years.

Allwin is not subject to income taxes.

As at March 31, 2002, the parent company, Kailong and Huaxin have estimated losses, for tax purposes, totalling approximately \$6,175,000, which may be applied against future taxable income. Accordingly, there is no tax expense charged to the Statement of Operations for the three months ended March 31, 2002 and 2001. The potential tax benefits arising from these losses have not been recorded in the financial statements. The Company evaluates its valuation allowance requirements on an annual basis based on projected future operations. When circumstances change and this causes a change in management's judgement about the realizability of deferred tax assets, the impact of the change on the valuation allowance is generally reflected in current income.

- (b) The tax effect of temporary differences that give rise to the Company's deferred tax asset (liability) are as follows:

	March 31, 2002
Tax losses carried forward	\$2,100,000
Stock-based compensation	-
Less: valuation allowance	(2,100,000)
	\$ -

A reconciliation of the federal statutory income tax to the Company's effective income tax rate, for the three months ended March 31, 2002 and 2001, is as follows:

	2002
Federal statutory income tax rate	34%
Change in valuation allowance	(34%)
Effective income tax rate	-

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

19

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

12. Stock Options and Warrants

(a) Stock Options Plans

The Company charged \$51,975 to income during the three months ended March 31, 2001 due to the exercise price of the vested options granted being below fair value of the Company's stock on the date of the grant. There were no options granted during the three months ended March 31, 2002.

Subsequent to March 31, 2002, the Company cancelled options to purchase 187,500 shares at a price of \$3.125 per share and granted options to purchase 920,000 shares at a price of \$1.70 per share.

The following is a summary of the employee stock option information for the period ended March 31, 2002:

	Shares	
Options outstanding at December 31, 1999	1,520,000	
Granted	1,737,500	
Forfeited	(107,500)	
Exercised	(107,000)	
Options outstanding at December 31, 2000		
Granted	195,000	
Forfeited	(137,500)	
Exercised	(131,000)	
Options outstanding at December 31, 2001 and March 31, 2002	2,969,500	

Options Outstanding			Options Exercisable		
Range of Exercise	Number	Weighted Average Remaining Contractual	Weighted Average Exercise	Number	Weighted Average Exercise

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

Prices	Outstanding	Life	Price	Exercisable	Price
\$0.01 - \$1.00	1,257,000	2.04	\$ 0.50	1,243,000	\$ 0.50
\$1.01 - \$2.00	175,000	4.33	\$ 1.79	175,000	\$ 1.79
\$2.01 - \$3.00	60,000	2.61	\$ 2.50	60,000	\$ 2.50
\$3.01 - \$4.00	1,477,500	3.6	\$ 3.13	1,477,500	\$ 3.13
	2,969,500	2.97	\$ 1.92	2,955,500	\$ 1.93
	=====	=====	=====	=====	=====

20

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

12. Stock Options and Warrants (continued)

The Company accounts for its stock-based compensation plan in accordance with APB Opinion No. 25, under which no compensation is recognized in connection with options granted to employees except if options are granted with a strike price below fair value of the underlying stock. The Company adopted the disclosure requirements SFAS No. 123, Accounting for Stock-Based Compensation. Accordingly, the Company is required to calculate and present the pro forma effect of all awards granted. For disclosure purposes, the fair value of each option granted to an employee has been estimated as of the date of grant using the Black-Scholes option pricing model with the following assumptions: risk-free interest rate of 5.5%, dividend yield 0%, volatility of 89%, and expected lives of approximately 0 to 5 years. Based on the computed option values and the number of the options issued, had the Company recognized compensation expense, the following would have been its effect on the Company's net loss:

	March 31, 2002
Net (loss) for the period:	
- as reported	\$ (937,878)
- pro-forma	(937,878)
Basic and diluted (loss) per share:	
- as reported	\$ (0.05)
- pro-forma	\$ (0.05)

(b) Warrants

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

Share purchase warrants outstanding as at December 31, 2001:

Number of Warrants	Underlying Shares	Exercise Price Per Share	Expiry Date
400,000	400,000	\$3.00	November 24, 2002
3,500,000	1,750,000	\$2.00	September 13, 2003
50,000	50,000	\$1.70	November 15, 2004
1,000,000	1,000,000	\$2.50	January 14, 2007

21

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

13. Related Party Transactions

(a) The Company incurred the following expenses to two directors of the Company:

	March 31, 2002
Management fees	\$57,500

(b) Pursuant to an agreement dated January 14, 2002, the Company entered into a Project Development Agreement with the President and Chief Executive Officer of the Company (the "President") to continue the research and development of G-CSF and Insulin for the Company. The Company will make payment for the development of G-CSF as follows:

- (i) US\$500,000 to be provided at the commencement of the research in the G-CSF Project;
- (ii) US\$500,000 to be provided when cell-line and related technology is established and animal experimentation commences in the G-CSF Project; and
- (iii) US\$300,000 to be provided when a permit for clinical trials for G-CSF has been issued by the State Drug Administration of China ("SDA"); and
- (iv) US\$200,000 to be provided when a new drug license for G-CSF is issued to Dragon by the SDA.
- (v) US\$500,000 to be paid as a bonus if the SDA issues the new drug license for G-CSF to Dragon before January 14, 2004.

The Company will make payment for the development of Insulin as follows:

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

- (i) US\$750,000 to be provided by at the commencement of the research in the Insulin Project;
- (ii) US\$750,000 to be provided when cell-line and related technology is established and animal experimentation commences in the Insulin Project;
- (iii) US\$300,000 to be provided when a permit for clinical trials for Insulin has been issued by the SDA; and
- (iv) US\$200,000 to be provided when a new drug license for Insulin is issued to Dragon by the SDA.
- (v) US\$500,000 to be paid as a bonus if the SDA issues the new drug license for Insulin to Dragon before January 14, 2005.

22

DRAGON PHARMACEUTICALS INC. & SUBSIDIARIES
Notes to Consolidated Financial Statements
March 31, 2002
(Expressed in U.S. Dollars)
(Unaudited - Prepared by Management)

13. Related Party Transactions (continued)

(a) For both the G-CSF and Insulin Projects:

- (i) If the Company elects to cease development of the project it will forfeit any payments made and lose ownership of the Project, but it will not be obligated to make any further payments toward the Project;
- (ii) if an application for permit for clinical trials is not submitted within three years with respect to the G-CSF Project by or four years with respect to the Insulin Project or if the SDA rejects the Project for technical or scientific reasons or If development of the Project is terminated by the President, then the President will refund to the Company all amounts paid, without interest or deduction, with respect to the Project with in six months

(c) see Notes 7,8, and 9 also.

14. Commitments

The Company has entered into operating lease agreements with respect to Huaxin's production plant in Nanjing, China for an amount of RMB 2,700,000 (US\$326,000) per annum until June 11, 2009, and the Company's administrative offices in Vancouver for an amount escalating from CDN\$200,000 to CDN\$230,000 (US\$126,000 to US\$145,000) per annum until March 31, 2007. Minimum payments required under the agreements are as follows:

2002	\$347,837
2003	452,312
2004	467,023
2005	468,104
2006	471,345
2007 - 2009	833,574
<hr/>	

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

Total	US\$3,040,195

15. Comparative Figures

Certain 2001 comparative figures have been reclassified to conform to the financial statement presentation adopted for 2002.

23

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation

The following discusses the Company's financial condition and results of operations based upon the Company's consolidated financial statements which have been prepared in accordance with generally accepted accounting principles. It should be read in conjunction with the Company's financial statements and the notes thereto and other financial information included in the Company's Form 10-KSB for the fiscal year ended December 31, 2001.

Overview

The Company (or "Dragon") was formed on August 22, 1989, under the name First Geneva Inc. First Geneva Investment's business was to evaluate businesses for possible acquisition. On July 28, 1998, First Geneva Investment entered into a share exchange agreement with Allwin Newtech. Allwin Newtech was formed in 1998 for the purpose of developing and marketing pharmaceutical drugs for sale in China. Prior to the acquisition of Allwin Newtech, First Geneva Investments had no operations. On September 21, 1998, First Geneva Investments changed its name to Dragon Pharmaceutical Inc.

On July 27, 1999, Dragon acquired a 75% interest in Nanjing Huaxin Biopharmaceuticals Co. Ltd. ("Huaxin"), which manufactures EPO in China. The Company increased the efficiencies in the production of EPO by improving a proprietary high-yield mammalian cell line and "vectoring process" which has been developed by Dragon. The Company successfully achieved commercial production during the last quarter of calendar 1999. In January 2002 the Company purchased the balance of Huaxin for \$1,400,000.

On September 6, 2000 Dragon incorporated Allwin Biotrade Inc. ("Biotrade"). Biotrade was incorporated for the purpose of marketing and distributing biopharmaceutical products outside China. On September 15, 2000 Dragon incorporated Dragon Pharmaceuticals (Canada) Inc. ("Dragon Canada"). Dragon Canada was incorporated for the purpose of researching and developing new biopharmaceutical products.

Results of Operations

Revenues. Revenue is generated from the sale of EPO in China by Huaxin and throughout the developing world by Biotrade. Revenue for the three-month period ending March 31, 2002 was \$1,372,808 compared to \$664,414 for the three-month period ending March 31, 2001. Sales in and outside of China were \$525,308 and \$847,500, respectively during the three-month period ending March 31, 2002. All sales during the three-month period ending March 31, 2001 were in China. Cost of sales for the three-months ended March 31, 2002 of \$190,524 is attributed to the production costs of the pharmaceutical products. The cost of sales for the three-months ended March 31, 2001 was \$146,920.

Interest income is related primarily to interest earned on cash received from the private placement of common stock received during the third quarter of 2001

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

and the last quarter of 1999. Interest income for the three-months period ending March 31, 2002 was \$33,607 compared to \$65,259 for the three-month period ended March 31, 2001. Interest income has decreased as the cash balance has decreased through the funding of operations.

Expenses. Total operating expenses for the three-months ended March 31, 2002 were \$2,153,768. The major expenses incurred in the first quarter of 2002 were research and development expenses of \$755,572 and the selling expenses of \$477,196 representing 35% and 22% of total expenses, respectively. The remaining major expense items are represented by administrative expenses.

24

Significant operating expenses for the three-months ended March 31, 2002 included consulting fees of \$148,737, loan interest of \$40,410, rent of \$61,546, salaries and benefits of \$141,686, \$78,390 in travel costs and management fees of \$76,193. Management fees include \$57,500 incurred to two directors for services during the first quarter of 2002.

Other significant expenses for the first quarter of 2002 include the depreciation of fixed assets and amortization of license and permit and land-use rights of \$181,658.

Comparatively, total operating expenses for the first quarter of 2001 were \$1,542,496. Selling expenses represented 37% total operating expenses during this period. Other major expenses for the three-month period ended March 31, 2001 included the depreciation of fixed assets and amortization of intangible assets of \$153,814, consulting fees of \$122,323, bad debt write offs of \$36,826, loan interest of \$33,993, rent of \$71,330, salaries of \$95,242 and management fees of \$35,125, including management fees of \$18,000 paid to a director for services rendered during the period.

Overall, expenditures have increased in 2001 over 2000 levels due to increased personnel and activity levels.

Net and Comprehensive Loss. Dragon had a net loss and a comprehensive loss of \$937,878 for the three-months ended March 31, 2002.

The Company's net loss for the three-month period ended March 31, 2001, was \$959,743, which includes a minority interest share of the loss of \$103,560. The comprehensive loss for the same period was \$856,183.

Basic and Diluted Net Loss Per Share

The Company's net loss per share has been computed by dividing the net loss for the period by the weighted average number of shares outstanding during three-months ended March 31, 2002. The loss per share for the three-month period ended March 31, 2002 was \$0.05. Common stock issuable upon the exercise of common stock options and common stock warrants have been excluded from the net loss per share calculations as their inclusion would be anti-dilutive.

Liquidity and Capital Resources

Dragon is a development stage pharmaceutical and biotechnological company that has commenced the manufacture and marketing of pharmaceutical products in China through its 75% equity interest in Nanjing Huaxin Biotech. Previously, the Company has raised funds through equity financings to fund its operations and to provide working capital. The Company may finance future operations through additional equity financings.

On October 14, 1999, the Company entered into securities purchase agreements with two investors located in Hong Kong. Under the terms of this agreement, the

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

investors purchased, in the aggregate, 600,000 shares of common stock at \$2.50 per share, with the Company raising in the aggregate \$1.5 million.

25

On December 31, 1999, the Company closed a private placement raising \$10,645,000 through the issue of 4,258,000 shares of common stock at a price of \$2.50 per share. \$600,000 of the gross proceeds from the December 1999 offering represented the conversion of the outstanding debt by the lenders into shares of common stock of the Company at a price of \$2.50 per share.

One million common shares were issued through the exercise of warrants that expired on September 30, 2000. These warrants were issued to shareholders through the acquisition of Allwin Newtech on August 17, 1998. Gross proceeds from the exercise of the warrants were \$1,000,000.

On September 14, 2001, the Company closed a private placement raising \$7,000,000 through the issue of 3,500,000 shares of common stock at a price of \$2.00 per share.

As of March 31, 2002, the Company had \$5,791,160 in unrestricted cash available, and working capital of \$5,220,416. This cash and working capital will be used to fund the ongoing operations and research and development of the Company for the next 21 months.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company is exposed to market risk, primarily related to foreign exchange. The Company maintains its accounting records in their functional currencies (i.e., U.S. dollars, Renminbi Yuan, and Canadian dollars respectively). They translate foreign currency transactions into their functional currency in the following manner.

At the transaction date, each asset, liability, revenue and expense is translated into the functional currency by the use of the exchange rate in effect at that date. At the period end, monetary assets and liabilities are translated into the functional currency by using the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in operations.

The following table sets forth the percentage of the Company's administrative expense by currency for the years ended December 31, 2000 and 2001 and quarters ended March 31, 2001 and 2002.

By Currency

	December 31, 2001 -----	December 31, 2002 -----
U.S. Dollar	22%	31%
Canadian Dollar	0%	12%
Renminbi yuan	78%	57%
Total	100%	100%

26

March 31, 2001 -----	March 31, 2002 -----
-------------------------	-------------------------

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 10-Q

U.S. Dollar	36%	41%
Canadian Dollar	0%	13%
Renminbi yuan	64%	45%
Total	100%	100%

Such administrative expense by currency may change from time to time. Further, the Company incurred expenses in China of \$427,000 and \$503,000 for the quarters ended March 31, 2001 and 2002, respectively, all of which were paid in RMB.

The Company has not entered into any material foreign exchange contracts to minimize or mitigate the effects of foreign exchange fluctuations on the Company's operations. The Company exchanges United States dollars to fund its Chinese operations. Based on prior years, the Company does not believe that it is subject to material foreign exchange fluctuations, however, no assurance can be given that this will not occur in the future.

As disclosed in Note 10 to the Company's financial statements, the Company has entered into a series of loans in the aggregate outstanding amount of \$2,609,168 as of March 31, 2002. The weighted average interest rate was 5.265% for the three months ended March 31, 2002. Some of these loans are due beginning on April 4, 2002 and ending on January 31, 2003. To the extent that there may be an increase in interest rates during this period, the Company could be adversely affected.

PART II. OTHER INFORMATION

Items 1, 2, 3, 4, 5 and 6

None.

27

Signatures

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

DRAGON PHARMACEUTICAL INC.
(registrant)

Dated: May 13, 2002

/s/ Matthew Kavanagh

Matthew Kavanagh
Director of Finance and Corporate
Compliance and Corporate Secretary
(Authorized to sign on behalf of the
registrant)